LLY

1,050.66

+4.16%↑

JNJ

245.54

+1.25%↑

ABBV

228.02

+1.45%↑

NVS

164.59

+1.17%↑

MRK

123.51

+1.02%↑

LLY

1,050.66

+4.16%↑

JNJ

245.54

+1.25%↑

ABBV

228.02

+1.45%↑

NVS

164.59

+1.17%↑

MRK

123.51

+1.02%↑

LLY

1,050.66

+4.16%↑

JNJ

245.54

+1.25%↑

ABBV

228.02

+1.45%↑

NVS

164.59

+1.17%↑

MRK

123.51

+1.02%↑

LLY

1,050.66

+4.16%↑

JNJ

245.54

+1.25%↑

ABBV

228.02

+1.45%↑

NVS

164.59

+1.17%↑

MRK

123.51

+1.02%↑

LLY

1,050.66

+4.16%↑

JNJ

245.54

+1.25%↑

ABBV

228.02

+1.45%↑

NVS

164.59

+1.17%↑

MRK

123.51

+1.02%↑

Home・Akciju saraksts・Cogent Biosciences Inc

Cogent Biosciences Inc

Atvērts

36.73 -3.67

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

36.33

Max

38.97

Galvenie mērījumi
By Trading Economics
Ienākumi	-7.4M -81M
EPS	-0.5
Darbinieki	205
EBITDA	-6.8M -79M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+39.74% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	3.4B 5.6B
Iepriekšējā atvēršanas cena	40.4
Iepriekšējā slēgšanas cena	36.73

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

4.88 / 5.87 Atbalsts un pretestība

Cogent Biosciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 22. febr. 23:55 UTC

Tirgus saruna

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

2026. g. 22. febr. 23:53 UTC

Tirgus saruna

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

2026. g. 22. febr. 23:53 UTC

Tirgus saruna

Key China Rates Likely to Be Held Steady for Now -- Market Talk

2026. g. 22. febr. 23:51 UTC

Tirgus saruna

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

2026. g. 22. febr. 23:35 UTC

Tirgus saruna

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

2026. g. 22. febr. 23:21 UTC

Peļņas

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

2026. g. 22. febr. 23:20 UTC

Peļņas

Nickel Industries 2025 Operating Profit US$126.4 Million

2026. g. 22. febr. 23:19 UTC

Peļņas

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

2026. g. 22. febr. 23:19 UTC

Peļņas

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

2026. g. 22. febr. 23:18 UTC

Peļņas

Nickel Industries Won't Pay a Final Dividend

2026. g. 22. febr. 23:16 UTC

Peļņas

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

2026. g. 22. febr. 21:35 UTC

Peļņas

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

2026. g. 22. febr. 21:34 UTC

Peļņas

Ampol Says F&I Australia, International Have Begun 2026 Strongly

2026. g. 22. febr. 21:34 UTC

Peļņas

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

2026. g. 22. febr. 21:33 UTC

Peļņas

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

2026. g. 22. febr. 21:33 UTC

Peļņas

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

2026. g. 22. febr. 21:28 UTC

Peļņas

Ampol Final Dividend A$0.60/Share

2026. g. 22. febr. 21:28 UTC

Peļņas

Ampol FY Revenue A$31.37 Billion, Down 10%

2026. g. 22. febr. 21:28 UTC

Peļņas

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

2026. g. 22. febr. 21:28 UTC

Peļņas

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

2026. g. 21. febr. 14:31 UTC

Iegādes, apvienošanās, pārņemšana

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

2026. g. 21. febr. 05:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 20. febr. 23:12 UTC

Iegādes, apvienošanās, pārņemšana

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

2026. g. 20. febr. 22:12 UTC

Peļņas

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

2026. g. 20. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 20. febr. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 20. febr. 21:23 UTC

Peļņas

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

2026. g. 20. febr. 21:20 UTC

Tirgus saruna

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

2026. g. 20. febr. 21:01 UTC

Iegādes, apvienošanās, pārņemšana

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

2026. g. 20. febr. 20:38 UTC

Tirgus saruna

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Salīdzinājums

Cenas izmaiņa

Cogent Biosciences Inc Prognoze

Cenas mērķis

By TipRanks

39.74% augšup

Prognoze 12 mēnešiem

Vidējais 52.18 USD 39.74%

Augstākais 67 USD

Zemākais 35 USD

Pamatojoties uz 12 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

12 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 12 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

4.88 / 5.87Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.